Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with aggressive non-Hodgkin's lymphoma (a type of blood cancer) who have already tried at least one standard chemotherapy treatment and one additional "rescue" treatment that did not work well enough.
• People with aggressive non-Hodgkin's lymphoma who were considered for a stem cell transplant from a donor but were found to be not suitable for it.
• People whose aggressive non-Hodgkin's lymphoma came back after receiving a donor stem cell transplant, provided it has been at least 100 days since the transplant, there is no sign of graft-versus-host disease (a complication of donor transplants), and no immune-suppressing medications have been taken for at least 30 days before joining.
• People who have lymphoma that has spread to the brain or spinal fluid, but only if that disease has been fully cleared by the time of joining (isolated brain-only lymphoma does not qualify).
• People whose cancer cells have been confirmed to carry a specific protein called CD19, detected through laboratory testing of a tissue or blood sample.
• People aged 18 to 75 years old, provided the treating doctor considers them fit enough to participate.
• People who have a sufficient level of a specific type of immune cell (CD3+ T cells) in their blood, measured at a baseline level of at least 100 per microlitre.
• People with a reasonable level of physical functioning, rated 0–2 on a standard medical scale used to assess how well a person can carry out daily activities (confirm with trial site).
• People who do not have active Hepatitis B, Hepatitis C, or HIV.
• Women who cannot become pregnant, or women who can become pregnant and have a negative pregnancy test within 7 days before starting a preparatory chemotherapy phase.
• People who have read, understood, and signed a consent form before any trial-related procedures begin.

Who may not be able to join:

• People who still have active lymphoma in the brain or spinal fluid at the time of joining.
• People who currently have, or have a history of, an autoimmune disease (where the immune system attacks the body) that could affect the brain or nervous system.
• People with serious, uncontrolled neurological conditions such as uncontrolled seizures, stroke, dementia, or paralysis.
• People who have had another type of cancer in the past, unless it was a minor skin cancer or a very early-stage cancer, or unless they have been cancer-free for 3 or more years.
• People with serious pre-existing lung disease, significantly reduced lung function (below a specific threshold on breathing tests), or active signs of lung inflammation seen on imaging scans.
• People whose heart is not pumping blood efficiently enough, based on a specific heart scan measurement falling below a set level.
• People whose kidneys are not filtering blood well enough, based on a standard calculation of kidney function.
• People with significantly reduced liver function based on blood test results, unless the treating doctor believes the poor results are caused directly by the lymphoma itself.
• People whose cancer is growing so rapidly that, in the treating doctor's judgement, it would prevent them from completing the trial treatment.
• People who are pregnant or currently breastfeeding.
• People who have received certain medications — including chemotherapy, steroids (except low-level replacement doses), specific immune-suppressing drugs, other experimental treatments, donor immune cell infusions, or radiation therapy — within 30 days before a blood collection procedure called apheresis; or rituximab within 2 weeks before that procedure (certain chemotherapy given directly into the spinal fluid may be permitted, but must stop at least 10 days before the trial treatment infusion).
• People who are able to have children (either women who can become pregnant or men who could father a child) and are not willing to use effective contraception from the time of joining until three months after receiving the trial treatment.
• People who are already taking part in another interventional clinical trial that could interact with this one, including other CAR T-cell trials.
• People who have received another experimental treatment within 4 weeks before the trial treatment infusion.
• People who have a condition affecting brain function that affects their legal capacity to make decisions as an adult.
• People who are under a court or official order to be held in an institution.

Important: Always verify eligibility with the trial site directly before applying.